Showing results (61-70 of 121) with videos related to
Sort By:
Pageof 13
Journal of Hepatology|October 27, 2012
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter studyEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Internal Medicine (Tokyo, Japan)|March 21, 2015
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infectionAkira Kawano, Eiichi Ogawa, Norihiro Furusyo, et al.Journal of Gastroenterology and Hepatology|November 22, 2011
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease StudyEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Atherosclerosis|December 22, 2014
Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS)Motohiro Shimizu, Norihiro Furusyo, Fujiko Mitsumoto, et al.Antiviral Research|January 28, 2014
Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infectionEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Journal of Gastroenterology and Hepatology|June 23, 2015
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infectionEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Journal of Gastroenterology and Hepatology|March 18, 2015
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis CEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 9, 2019
Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort studyEiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 22, 2019
Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysisEiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, et al.Antiviral Research|November 7, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosisEiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, et al.Pageof 13